期刊
CARCINOGENESIS
卷 35, 期 12, 页码 2822-2830出版社
OXFORD UNIV PRESS
DOI: 10.1093/carcin/bgu220
关键词
-
类别
资金
- (FPU) from the Spanish Ministry of Education
- Spanish National Cancer Research Center
- European Research Council (Advanced ERC Grant) [233270]
- Framework Program 7 of the European Union (RISK-IR) [323267]
- Spanish Ministry of Economy [SAF2008-02959]
- Regional Government of Madrid [S2010/BMD-2303]
- Botin Foundation
- Ramon Areces Foundation
- AXA Foundation
Nucleolar disruption has recently emerged as a relevant means to activate p53 through inhibition of HDM2 by ribosome-free RPL11. Most drugs that induce nucleolar disruption also possess important genotoxic activity, which can have lasting mutagenic effects. Therefore, it is of interest to identify compounds that selectively produce nucleolar disruption in the absence of DNA damage. Here, we have performed a high-throughput screening to search for nucleolar disruptors. We have identified an acridine derivative (PubChem CID-765471) previously known for its capacity to activate p53 independently of DNA damage, although the molecular mechanism underlying p53 activation had remained uncharacterized. We report that CID-765471 produces nucleolar disruption by inhibiting ribosomal DNA transcription in a process that includes the selective degradation of the RPA194 subunit of RNA polymerase I. Following nucleolar disruption, CID-765471 activates p53 through the RPL11/HDM2 pathway in the absence of detectable DNA damage. In a secondary screening of compounds approved for medical use, we identify two additional acridine derivatives, aminacrine and ethacridine, that operate in a similar manner as CID-765471. These findings provide the basis for non-genotoxic chemotherapeutic approaches that selectively target the nucleolus.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据